1. Oberlin, O.; Rey, A.; Lyden, E.; et al. Prognostic factors in
metastatic rhabdomyosarcomas: Results of a pooled analysis from United
States and European Cooperative Groups. J Clin Oncol. 2008 May
10;26(14):2384-9.
2. Compostella, A.; Affinita, M.C.; Casanova, M.; et al.
Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma
in children: Report from the AIEOP Soft Tissue Sarcoma Committee.
Tumori. 2019 Apr;105(2):138-143.
3. Honoré, C.; Delhorme, J.B.; Nassif, E. et al. Can we cure patients
with abdominal Desmoplastic Small Round Cell Tumor? Results of a
retrospective multicentric study on 100 patients. Surg Oncol 2019
Jun;29:107-112.
4. Chisholm, J.C.; Merks, J.H.M.; Casanova, M.;et al. Open-label,
multicentre, randomised, phase II study of the EpSSG and the ITCC
evaluating the addition of bevacizumab to chemotherapy in childhood and
adolescent patients with metastatic soft tissue sarcoma (the BERNIE
study). Eur J Cancer. 2017 Sep;83:177-184.
5. Jin, W. The Role of Tyrosine Kinases as a Critical Prognostic
Parameter and Its Targeted Therapies in Ewing Sarcoma. Front Cell Dev
Biol. 2020 Jul 9;8:613.
6. Womer, R.B.; West, D.C.; Krailo, M.D.; et al. Randomized controlled
trial of interval-compressed chemotherapy for the treatment of localized
ewing sarcoma: A report from the children’s oncology group. J Clin
Oncol. 2012 Nov 20;30(33):4148-54
7. Weigel, B.J.; Lyden, E.; Anderson, J.R.; et al. Intensive multiagent
therapy, including dose-compressed cycles of ifosfamide/etoposide and
vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in
patientswith high-risk rhabdomyosarcoma: A report from the children’s
oncology group. J Clin Oncol. 2016 Jan 10;34(2):117-22.
8. Wagner, L.M. Fifteen years of irinotecan therapy for pediatric
sarcoma: where to next? Clin Sarcoma Res. 2015 Aug 28;5:20
9. Bisogno, G.; Ferrari, A.; Bergeron, C.; et al. The IVADo regimen - A
pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin
in children with metastatic soft tissue sarcoma: A pilot study on behalf
of the European pediatric soft tissue sarcoma study group.
Cancer. 2005 Apr 15;103(8):1719-24.
10. Bisogno, G.; Jenney, M.; Bergeron, C.; et al. Addition of
dose-intensified doxorubicin to standard chemotherapy for
rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised
controlled, phase 3 trial Lancet Oncol. 2018 Aug;19(8):1061-1071.
11. Mascarenhas, L.; Felgenhauer, J.L.; Bond, M.C.; et al. Pilot Study
of Adding Vincristine, Topotecan, and Cyclophosphamide to
Interval-Compressed Chemotherapy in Newly Diagnosed Patients With
Localized Ewing Sarcoma: A Report From the Children’s Oncology Group.
Pediatr Blood Cancer. 2016 Mar;63(3):493-8